[$$] Sales of Johnson & Johnson’s New Hepatitis C Drug Soar

[at The Wall Street Journal] – Sales of Johnson & Johnson’s new hepatitis C drug soared during its first full quarter on the market, in another sign of strong demand—and high prices—for a new generation of treatments for the liver-damaging … more

View todays social media effects on JNJ

View the latest stocks trending across Twitter. Click to view dashboard

See who Johnson is hiring next, click here to view